Skip to content

TriangleGet started

← Full study record

NCT03188536 · OUTCOME

Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) · Source last updated 2020-10-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Day 1

What was measured

Clinical and Sociodemographic variables categorized by treatment selection(immunomodulators\[IMiDs\],proteasome inhibitor\[PI\]+IMiDs,PI,monoclonal antibodies\[mAb\]): Age,sex(male/female),prior treatment lines(0,1,2,3 or more),prior relapses(0,1,2,3 or more),ISS disease stage(I:low risk,β2-Microglobulin\<3.5mg/L,albumin≥3.5g/dL,II:not stage I or III,III:high risk,β2-Microglobulin≥5.5mg/L),CRAB signs(serum calcium\>0.25mmol/L upper limit of normal,renal failure-creatinine clearance\<40mL/min/serum creatinine\>117μmol/L,anemia:reduction of hemoglobin(Hb)\>2g/dL below lower limit of normal or Hb\<10g/dL,bone lesions 1/more osteolytic lesion),risk according to cytogenetic profile(standard:trisomies,t\[11;14\];t\[6;14\];high:d\[17p\],t\[14;16\],t\[14;20\],other),other clinical variables:medullary/extramedullary plasmacytomas,osteopenia,fractures,neurological symptoms,infections,concomitant diseases:diabetes, neuropathy, COPD, cardiovascular disease, liver failure, psychiatric, neurological disorders.

Analysis population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Percentages were rounded off.

Groups in this outcome

Multiple Myeloma (MM) Participants

Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	276

Reported measurements

Age, 38-85 years, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100	Not reported	Not reported	Not reported	Not reported

Age, 43-76 years, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100	Not reported	Not reported	Not reported	Not reported

Age, 47-84 years, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100	Not reported	Not reported	Not reported	Not reported

Age, 39-80 years, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100	Not reported	Not reported	Not reported	Not reported

Age, 53-90 years, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100	Not reported	Not reported	Not reported	Not reported

Sex, Male, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	49.4	Not reported	Not reported	Not reported	Not reported

Sex, Female, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.6	Not reported	Not reported	Not reported	Not reported

Sex, Male, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	61.2	Not reported	Not reported	Not reported	Not reported

Sex, Female, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	38.8	Not reported	Not reported	Not reported	Not reported

Sex, Male, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	47.1	Not reported	Not reported	Not reported	Not reported

Sex, Female, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	52.9	Not reported	Not reported	Not reported	Not reported

Sex, Male, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	55.7	Not reported	Not reported	Not reported	Not reported

Sex, Female, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	44.3	Not reported	Not reported	Not reported	Not reported

Sex, Male, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	57.7	Not reported	Not reported	Not reported	Not reported

Sex, Female, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	42.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 1, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.6	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 2, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	28.1	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 3 or more, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	21.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 1, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	63.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 2, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	16.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 3 or more, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.4	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 1, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	44.1	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 2, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	35.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 3 or more, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.6	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 1, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	26.2	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 2, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	29.5	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 3 or more, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	44.3	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 1, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.5	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 2, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	26.9	Not reported	Not reported	Not reported	Not reported

Prior lines of treatment, 3 or more, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	61.5	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 0, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	43.8	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 1, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	31.5	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 2, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	12.4	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 3 and more, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	12.4	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 0, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	49.0	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 1, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	36.7	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 2, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	2.0	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 3 or more, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	12.2	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 0, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	47.1	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 1, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	32.4	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 2, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	2.9	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 3 or more, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	17.6	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 0, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	27.9	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 1, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	26.2	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 2, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	18.0	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 3 or more, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	27.9	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 0, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.5	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 1, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	26.9	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 2, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.1	Not reported	Not reported	Not reported	Not reported

Number of prior relapses, 3 or more, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	38.5	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage I, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	65

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	38.5	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage II, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	65

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	38.5	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage III, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	65

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.1	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage I, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	39

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	51.3	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage II, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	39

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	28.2	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage III, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	39

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.5	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage I, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	24

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.8	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage II, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	24

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	54.2	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage III, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	24

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	25.0	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage I, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	40.0	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage II, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	32.0	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage III, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	50

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	28.0	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage I, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	21

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.8	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage II, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	21

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.8	Not reported	Not reported	Not reported	Not reported

ISS Disease Stage III, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	21

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	52.4	Not reported	Not reported	Not reported	Not reported

CRAB Signs, None, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	29.2	Not reported	Not reported	Not reported	Not reported

CRAB Signs, Some, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	70.8	Not reported	Not reported	Not reported	Not reported

CRAB Signs, None, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	14.3	Not reported	Not reported	Not reported	Not reported

CRAB Signs, Some, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	85.7	Not reported	Not reported	Not reported	Not reported

CRAB Signs, None, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.6	Not reported	Not reported	Not reported	Not reported

CRAB Signs, Some, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	79.4	Not reported	Not reported	Not reported	Not reported

CRAB Signs, None, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	31.1	Not reported	Not reported	Not reported	Not reported

CRAB Signs, Some, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	68.9	Not reported	Not reported	Not reported	Not reported

CRAB Signs, None, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.1	Not reported	Not reported	Not reported	Not reported

CRAB Signs, Some, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	76.9	Not reported	Not reported	Not reported	Not reported

Comorbidities, None, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	41.6	Not reported	Not reported	Not reported	Not reported

Comorbidities, Some, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	58.4	Not reported	Not reported	Not reported	Not reported

Comorbidities, None, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	49.0	Not reported	Not reported	Not reported	Not reported

Comorbidities, Some, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	51.0	Not reported	Not reported	Not reported	Not reported

Comorbidities, None, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	35.3	Not reported	Not reported	Not reported	Not reported

Comorbidities, Some, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	64.7	Not reported	Not reported	Not reported	Not reported

Comorbidities, None, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	32.8	Not reported	Not reported	Not reported	Not reported

Comorbidities, Some, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	67.2	Not reported	Not reported	Not reported	Not reported

Comorbidities, None, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.1	Not reported	Not reported	Not reported	Not reported

Comorbidities, Some, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	76.9	Not reported	Not reported	Not reported	Not reported

Risk, High, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	10

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Risk, Standard, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	10

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Risk, High, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	12

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	41.7	Not reported	Not reported	Not reported	Not reported

Risk, Standard, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	12

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	58.3	Not reported	Not reported	Not reported	Not reported

Risk, High, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	4

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Risk, Standard, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	4

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Risk, High, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	15

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	60.0	Not reported	Not reported	Not reported	Not reported

Risk, Standard, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	15

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	40.0	Not reported	Not reported	Not reported	Not reported

Risk, High, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	4

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Risk, Standard, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	4

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	50.0	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	84

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	15.5	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	84

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	84.5	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	44

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	25.0	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	44

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	75.0	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	14.7	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	85.3	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	58

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	8.6	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	58

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	91.4	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	25

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	16.0	Not reported	Not reported	Not reported	Not reported

Medullary Plasmacytoma, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	25

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	84.0	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	86

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	12.8	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	86

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	87.2	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	48

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	33.3	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	48

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	66.7	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.8	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	88.2	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	6.7	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	93.3	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	25

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	24.0	Not reported	Not reported	Not reported	Not reported

Extramedullary Plasmacytoma, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	25

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	76.0	Not reported	Not reported	Not reported	Not reported

Osteopenia, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	88

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.9	Not reported	Not reported	Not reported	Not reported

Osteopenia, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	88

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	76.1	Not reported	Not reported	Not reported	Not reported

Osteopenia, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	48

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	6.3	Not reported	Not reported	Not reported	Not reported

Osteopenia, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	48

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	93.8	Not reported	Not reported	Not reported	Not reported

Osteopenia, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	8.8	Not reported	Not reported	Not reported	Not reported

Osteopenia, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	91.2	Not reported	Not reported	Not reported	Not reported

Osteopenia, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	13.3	Not reported	Not reported	Not reported	Not reported

Osteopenia, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	60

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	86.7	Not reported	Not reported	Not reported	Not reported

Osteopenia, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	23.1	Not reported	Not reported	Not reported	Not reported

Osteopenia, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	76.9	Not reported	Not reported	Not reported	Not reported

Fractures, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	15.7	Not reported	Not reported	Not reported	Not reported

Fractures, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	84.3	Not reported	Not reported	Not reported	Not reported

Fractures, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	18.4	Not reported	Not reported	Not reported	Not reported

Fractures, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	81.6	Not reported	Not reported	Not reported	Not reported

Fractures, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.8	Not reported	Not reported	Not reported	Not reported

Fractures, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	88.2	Not reported	Not reported	Not reported	Not reported

Fractures, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	14.8	Not reported	Not reported	Not reported	Not reported

Fractures, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	85.2	Not reported	Not reported	Not reported	Not reported

Fractures, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	15.4	Not reported	Not reported	Not reported	Not reported

Fractures, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	84.6	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	10.1	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	89.9	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	10.2	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	89.8	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	5.9	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	94.1	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	1.6	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	98.4	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.5	Not reported	Not reported	Not reported	Not reported

Neurological Symptoms, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	88.5	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	5.6	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	94.4	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	8.2	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	91.8	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	5.9	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	94.1	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	0.0	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	100.0	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	7.7	Not reported	Not reported	Not reported	Not reported

MM Related Neurological Symptoms, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	92.3	Not reported	Not reported	Not reported	Not reported

Infections, Yes, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	14.6	Not reported	Not reported	Not reported	Not reported

Infections, No, IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	89

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	85.4	Not reported	Not reported	Not reported	Not reported

Infections, Yes, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	20.4	Not reported	Not reported	Not reported	Not reported

Infections, No, PI + IMiDs

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	49

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	79.6	Not reported	Not reported	Not reported	Not reported

Infections, Yes, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	14.7	Not reported	Not reported	Not reported	Not reported

Infections, No, PI

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	34

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	85.3	Not reported	Not reported	Not reported	Not reported

Infections, Yes, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.5	Not reported	Not reported	Not reported	Not reported

Infections, No, mAb

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	61

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	88.5	Not reported	Not reported	Not reported	Not reported

Infections, Yes, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	11.5	Not reported	Not reported	Not reported	Not reported

Infections, No, Other

Analysis denominator · Participants

Group	Source count
Multiple Myeloma (MM) Participants	26

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma (MM) Participants	88.5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
100
denoms
counts
group Id
OG000
value
89
units
Participants
title
Age, 38-85 years, IMiDs
categories
measurements
group Id
OG000
value
100
denoms
counts
group Id
OG000
value
49
units
Participants
title
Age, 43-76 years, PI + IMiDs
categories
measurements
group Id
OG000
value
100
denoms
counts
group Id
OG000
value
34
units
Participants
title
Age, 47-84 years, PI
categories
measurements
group Id
OG000
value
100
denoms
counts
group Id
OG000
value
61
units
Participants
title
Age, 39-80 years, mAb
categories
measurements
group Id
OG000
value
100
denoms
counts
group Id
OG000
value
26
units
Participants
title
Age, 53-90 years, Other
categories
measurements
group Id
OG000
value
49.4
denoms
counts
group Id
OG000
value
89
units
Participants
title
Sex, Male, IMiDs
categories
measurements
group Id
OG000
value
50.6
denoms
counts
group Id
OG000
value
89
units
Participants
title
Sex, Female, IMiDs
categories
measurements
group Id
OG000
value
61.2
denoms
counts
group Id
OG000
value
49
units
Participants
title
Sex, Male, PI + IMiDs
categories
measurements
group Id
OG000
value
38.8
denoms
counts
group Id
OG000
value
49
units
Participants
title
Sex, Female, PI + IMiDs
categories
measurements
group Id
OG000
value
47.1
denoms
counts
group Id
OG000
value
34
units
Participants
title
Sex, Male, PI
categories
measurements
group Id
OG000
value
52.9
denoms
counts
group Id
OG000
value
34
units
Participants
title
Sex, Female, PI
categories
measurements
group Id
OG000
value
55.7
denoms
counts
group Id
OG000
value
61
units
Participants
title
Sex, Male, mAb

denoms

counts
group Id
OG000
value
276
units
Participants

description

Clinical and Sociodemographic variables categorized by treatment selection(immunomodulators\[IMiDs\],proteasome inhibitor\[PI\]+IMiDs,PI,monoclonal antibodies\[mAb\]): Age,sex(male/female),prior treatment lines(0,1,2,3 or more),prior relapses(0,1,2,3 or more),ISS disease stage(I:low risk,β2-Microglobulin\<3.5mg/L,albumin≥3.5g/dL,II:not stage I or III,III:high risk,β2-Microglobulin≥5.5mg/L),CRAB signs(serum calcium\>0.25mmol/L upper limit of normal,renal failure-creatinine clearance\<40mL/min/serum creatinine\>117μmol/L,anemia:reduction of hemoglobin(Hb)\>2g/dL below lower limit of normal or Hb\<10g/dL,bone lesions 1/more osteolytic lesion),risk according to cytogenetic profile(standard:trisomies,t\[11;14\];t\[6;14\];high:d\[17p\],t\[14;16\],t\[14;20\],other),other clinical variables:medullary/extramedullary plasmacytomas,osteopenia,fractures,neurological symptoms,infections,concomitant diseases:diabetes, neuropathy, COPD, cardiovascular disease, liver failure, psychiatric, neurological disorders.

groups

description
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
id
OG000
title
Multiple Myeloma (MM) Participants

param Type

NUMBER

population Description

All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Percentages were rounded off.

reporting Status

POSTED

time Frame

Day 1

title

Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice